ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ERGO Ergomed Plc

1,346.00
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1,346.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Ergomed plc John Dawson appointed Senior Independent Director (3547I)

02/12/2022 7:00am

UK Regulatory


Ergomed (LSE:ERGO)
Historical Stock Chart


From Apr 2022 to Apr 2024

Click Here for more Ergomed Charts.

TIDMERGO

RNS Number : 3547I

Ergomed plc

02 December 2022

PRESS RELEASE

John Dawson CBE Appointed Senior Independent Director

Guildford, UK - 2 December 2022: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that John Dawson, CBE has been appointed Senior Independent Director of the Board with immediate effect. Mr Dawson has served as an independent Non-Executive Director and Chair of the Audit Committee of the Ergomed Board of Directors since March 2022.

ENDS

Enquiries:

 
 Ergomed plc                                                     Tel: +44 (0) 1483 402 
                                                                                   975 
 Miroslav Reljanović (Executive Chairman) 
 Richard Barfield (Chief Financial Officer) 
  Keith Byrne (Senior Vice-President, Capital 
  Markets & Strategy) 
 
 Numis (Nominated Advisor and Joint Broker)                  Tel: +44 (0) 20 7260 1000 
 Freddie Barnfield / Euan Brown (Nominated 
  Adviser) 
 James Black (Broker) 
 
   Peel Hunt LLP (Joint Broker)                                   Tel: +44 (0) 20 7418 
   James Steel / Dr Christopher Golden                                            8900 
 Consilium Strategic Communications - for                    Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Matthew Neal                              ergomed@consilium-comms.com 
 Angela Gray 
 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOATBBBTMTTMTMT

(END) Dow Jones Newswires

December 02, 2022 02:00 ET (07:00 GMT)

1 Year Ergomed Chart

1 Year Ergomed Chart

1 Month Ergomed Chart

1 Month Ergomed Chart

Your Recent History

Delayed Upgrade Clock